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Simple Summary: Although effective in the majority of patients, the progression-free survival (PFS)
to imatinib treatment can vary widely in effectiveness. Based on the known predictive role of tyrosine
kinase (KIT) and platelet-derived growth factor receptor α (PDGRA) tumor genotypes, the differential
clinical response to first-line imatinib treatment might be related to the different types and gene
locations of the mutations. In our study, metastatic patients with gastrointestinal stromal tumors
(GIST)-carrying KIT exon 11 deletion or a deletion/insertion involving codons 557/558 showed
significantly shorter PFS to imatinib compared with those with deletion in codons other than 557/558
and patients with exon 11 duplication, insertion or single nucleotide variants (SNVs). Conversely, the
latter subgroup showed the longest PFS first-line to imatinib. These results highlight the predictive
role of pathogenic variant (PV) type and codon location in GIST, and can support stratification via
mutational status in future clinical trials.
Abstract: In previous studies on localized GISTs, KIT exon 11 deletions and mutations involv-
ing codons 557/558 showed an adverse prognostic influence on recurrence-free survival. In the
metastatic setting, there are limited data on how mutation type and codon location might contribute
to progression-free survival (PFS) variability to first-line imatinib treatment. We analyzed the type
and gene location of KIT and PDGFRA mutations for 206 patients from a GIST System database
prospectively collected at an Italian reference center between January 2005 and September 2020.
By describing the mutational landscape, we focused on clinicopathological characteristics according
to the critical mutations and investigated the predictive role of type and gene location of the KIT exon
11 mutations in metastatic patients treated with first-line imatinib. Our data showed a predictive
impact of KIT exon 11 pathogenic variant on PFS to imatinib treatment: patients with deletion or
insertion/deletion (delins) in 557/558 codons had a shorter PFS (median PFS: 24 months) compared
to the patients with a deletion in other codons, or duplication/insertion/SNV (median PFS: 43 and
49 months, respectively) (p < 0.001). These results reached an independent value in the multivariate
model, which showed that the absence of exon 11 deletions or delins 557/558, the female gender,
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primitive tumor diameter (≤5 cm) and polymorphonuclear leucocytosis (>7.5 109/L) were signifi-
cant prognostic factors for longer PFS. Analysis of the predictive role of PDGFRA PVs showed no
significant results. Our results also confirm the aggressive biology of 557/558 deletions/delins in
the metastatic setting and allow for prediction at the baseline which GIST patients would develop
resistance to first-line imatinib treatment earlier.
Keywords: gastrointestinal stromal tumors; GIST; imatinib; KIT; mutations; predictive biomarkers
1. Introduction
The discovery of constitutive activating mutations in the proto-oncogene receptor
tyrosine kinase (KIT) or platelet-derived growth factor receptor α (PDGFRA) oncogenes
as molecular drivers of most gastrointestinal stromal tumors (GISTs) [1,2] has radically
changed our knowledge on their tumor biology. Activating mutations in KIT (70–80%
of GISTs) or PDGFRA (5–10% of GISTs) disrupt the normal autoinhibitory state of recep-
tor tyrosine kinase (RTK), leading to the constitutive, ligand-independent activation of
Ras/Raf/MAPK, JAK/STAT3 and PI3K/Akt/mTOR downstream pathways, ultimately re-
sulting in increased cell proliferation [3,4]. The resulting aberrant receptor tyrosine kinases,
known to be clinically excellent therapeutic targets, have transformed GISTs into a model
for successful molecular targeted therapy [5,6]. Indeed, KIT and PDGRFA represent not only
key diagnostic markers but, more importantly, they also present prognostic and predictive
significance, providing a powerful tool for the therapy selection process [7–11]. Tumor mu-
tational status is particularly important because GIST patients show great variability in
response to medical treatment, depending on the mutation’s location [12]. GISTs with KIT
exon 11 mutations are the most responsive to standard first-line imatinib 400 treatment,
with a response rate of 80% [13], whereas KIT exon 9 mutations are associated with a lower
response rate of 45%. These patients benefit from the higher dose of 800 mg/die [13,14].
Although most GISTs with KIT exon 11 mutations are highly sensitive to front-line imatinib,
progression-free survival (PFS) can vary widely in this subset of patients [15–17]. In previ-
ous studies on localized GISTs treated with surgery and adjuvant imatinib, different types
of KIT exon 11 mutations (mainly deletions or mutations that involve codons 557 and/or
558) showed an adverse prognostic influence on recurrence-free survival (RFS) [18–20].
Indeed, there are limited data on how mutation type and codon location might contribute
to clinical behavior and the variability of response to therapy in metastatic GISTs treated
with first-line imatinib. A previous study investigated the predictive role of KIT exon 11
mutations in a cohort of advanced patients, with a primary interest in pathogenic variant
(PV) location. This showed that patients with alterations affecting codons 557/558 devel-
oped secondary resistance more rapidly compared to patients carrying the most distal exon
11 mutations (codon 559 or downstream) [21]. However, the potential predictive impact of
specific PV type needs further elucidation in the metastatic setting.
Based on this rationale, we focused on the clinicopathological characteristics according
to critical mutations by describing the mutational landscape in a broad cohort of GIST
patients and investigated the predictive role of the type and codon location of the KIT exon
11 mutations in metastatic GIST patients treated with first-line imatinib.
2. Results
2.1. Pathogenic Variant Classification of GIST Patients
PV classification was assessed for 206 GIST patients; in Figure 1, we describe the
genetic landscape of GIST patients according to exact PV type and codon location.
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Of 206 patients, 188 showed PV mutually exclusive of KIT (174 patients, 84.5%) or 
PDGFRA (14 patients, 6.8%) genes. In the group of 154 patients with KIT exon 11 muta-
tions (74.8%), 95 deletions (del) (61.7%), 38 single nucleotide variants (SNVs) (24.7%), 10 
duplications (6.5%), 9 insertions/deletions (delins) (5.8%) and 2 insertions (1.3%) were 
identified. The most common site of KIT exon 11 mutations included codons 550–560. 
Sixty out of 154 (39%) patients carried deletions that spanned the critical codons 557 
and/or 558. These deletions were lost either as specific isolated 557/558 deletions, such as 
the most common W557_K558del (n.16 patients; 7.8% of all GIST patients), or as part of 
larger deletions that included mutation positions upstream of codon 557 (p.K550_K558del; 
p.K550_E554del) and downstream of codon 558. Among the latter are included several 
deletions involving codons 568–570, which are located in the distal part of the exon and 
which seem to have an important and specific effect on KIT signaling pathways [22]. These 
PVs, however, are characterized by a low frequency (with less than three cases for each 
PV). Among the other types of KIT exon 11 PVs, SNVs mainly affecting codons 557–560 
were particularly frequent. The p.W557R, which leads to a missense substitution in posi-
tion 557 of the KIT protein with the substitution of tryptophan (W) with arginine (R), was 
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Of 206 patients, 1 8 showed PV m tually exclusive of KIT (174 patients, 84.5%)
or PDGFRA (14 patients, 6.8%) genes. In the group of 154 patients with KIT exon 11
mutations (74.8%), 95 deletions (del) (61.7%), 38 si gle nucleotide variants (SNVs) (24.7%),
10 duplications (6.5%), 9 insertions/deletions (delins) (5.8%) and 2 insertions (1.3%) ere
identified. The most common site of KIT exon 11 mutations included codons 550–560.
Sixty out of 154 (39 ) patients carried deletions that spanned the critical codons 557
and/or 558. These deletions were lost either as specific isolated 557/558 deletions, such as
the ost co on 557_K558del (n.16 patients; 7.8% of all GIST patients), or as part of
larger deletions that included mutation positions upstream of codon 557 (p.K550_K558del;
p.K550_E554del) and downstream of codon 558. Among the latter are included several
deletions involving codons 568–570, which are located in the distal part of the exon and
which seem to have an important and specific effect on KIT signaling pathways [22]. These
PVs, however, are characterized by a low frequency (with less than three cases for each PV).
Among the other types of KIT exon 11 PVs, SNVs mainly affecting codons 557–560 were
particularly frequent. The p.W557R, which leads to a missense substitution in position
557 of the KIT protein with the substitution of tryptophan (W) with arginine (R), was
found in 10 GIST patients (4.9%). This variant, also known as c.1669T>C, results in a single
nucleotide change with the substitution of a thymine fora cytosine in position 1669 of the
coding sequence of the gene.
In KIT exon 9, which encodes for the extracellular domain, the most common PV
identified was the A502_Y503 duplication (n. 15 patients; 75% of exon 9 PVs; 7.3% of all
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GIST patients), which mimics the conformational change that the extracellular KIT receptor
undergoes upon ligand bounding.
Concerning the PDGFRA gene, most mutations were identified in exon 18 (n.11
patients; 78.6% of PDGFRA PVs; 5.3% of the total GIST patients). The most prevalent
PV was the known imatinib-resistant p.D842V (n.5 patients, 1.9% of all patients; 45.4%
of all exon 18 PDGFRA mutated GISTs), a SNV involving the second kinase domain
and consisting of a single substitution at position 842 in the A-loop of an aspartic acid
(D) by a valine (V). Rarely, in-frame deletions (p.D842_M844del) or deletions/insertions
(p.D842_I843delinsV) of different lengths or other SNVs (p.N848K) were detected. Finally,
the PDGFRA exon 12 PVs 3 (1.5%) were equally rare, with one deletion (p.W559_R560del)
and two SNVs (p.P581S) observed. The detailed number of patients for each mutation type
and the description of the corresponding pathogenic variants are included in Table 1.
Table 1. Number of GIST patients with known KIT and PDGFRA mutational status. The description is based on affected
gene and exon, mutation type (deletion, deletion/insertion, duplication, insertion and single nucleotide variant) and exact
KIT or PDGFRA pathogenic variant.





Duplication 15 (7.3%) p.A502_Y503dup 15
Insertion 3 (1.5%) p.Y503_F504insAY 3
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Table 1. Cont.












Deletion 1 (0.5%) p.W559_R560del 1
SNV 2 (1%) p.P581S 2
Exon 18
11 (5.3%)
Deletion 1 (0.5%) p.D842_M844del 1
Deletion/Insertion 1 (0.5%) p.D842_I843delinsV 1
SNV 5 (1.9%) p.D842V 5




- - - -
* Others: PVs with numbers < 2. SNV: single nucleotide variant.
2.2. Metastatic GIST Patients
2.2.1. Clinicopathological Characteristics According to Critical Mutations
In the group of 80 metastatic patients, 60 (75%) harbored a KIT exon 11 PV and 10
(12.5%) a KIT exon 9 PV, while PDGRFA mutations were found in 7 patients (8.7%) and
KIT/PDGFRA wild-type genotypes were found in 3 patients (3.8%). Among the KIT exon
11 mutated patients, 25 (31.3%) showed exon 11 deletions or delins involving 557 and/or
558 codons and 35 patients (43.7%) had a deletion in codons other than 557/558 or other
PV types (duplication, insertion or SNV).
The patients with GIST who carried deletions or delins in codons 557/558 were
predominantly male (64%), with gastric GISTs (60%), a primitive tumor diameter of >5 cm
(92%) and a mitotic index of >5/50 HPF (76%), without predominant hepatic (40%) or
peritoneal (44%) metastatic involvement. Patients with GIST who carried KIT exon 11 PVs
not including 557/558 deletions or delins showed tumors that most frequently originated
in the small bowel (site of origin, small bowel 51.5% vs. stomach 22.8%), most frequently
had large primitive tumors (diameter > 5 cm 77.2% vs. diameter ≤ 5 cm 22.8% of patients)
and most frequently had a high median mitotic rate (mitosis >5/50 HPF 62.8% vs. mitosis
≤ 5/50 HPF 37.2% of patients).
The most common KIT exon 9 PV was the A502_Y503dup exon (8 out of 10 patients,
10% of all GISTs). These patients were mainly women (62.5%), with tumors frequently of
small bowel origin (five out of eight tumors; 62.5%), a median mitotic rate of >5/50 HPF
and a primitive tumor diameter of >5 cm in 75% of patients. The remainder of patients had
PDGFRA-mutated GISTs, including two patients with D842V PV, and only three (3.8%) of
these were KIT/PDGFRA WT GISTs.
Baseline clinical and pathological characteristics according to critical mutations are
summarized in Table 2.
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Table 2. The clinical and pathological characteristics of metastatic GIST patients, according to the type and location of the
critical mutations. The patients were classified based on genotyping as follows: (i) KIT exon 11 deletion or deletion/insertion
involving 557 and/or 558 codons versus other KIT exon 11 PVs; (ii) KIT exon 9 A502-Y503 codon duplication versus other
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SNV: single nucleotide variant; WT: wild type. * Comparison exon 11 del or delins 557 and/or 558 versus other exon 11 mutations; 1 Other
mutations than deletion or deletion/insertion codons 557 and/or 558; 2 Others mutations include one insertion (p.Y503_F504insAY) and
one SNV (p.S464L).
2.2.2. Outcome Analysis and Objective Response in KIT Exon 11 Metastatic Patients
We focused on the KIT exon 11 genotypic landscape because these are the most
common molecular alterations in GISTs and, at the same time, they show wide variability
in the duration of their response to imatinib. We classified the patients treated with
first-line imatinib and KIT exon 11 mutation in two groups: (i) KIT Exon 11 deletion or
insertion/deletion in codons 557 and/or 558 (named “D-557/8”); (ii) mutations other than
those in D-557/8 (named “No-D-557/8”). Twenty-five (25) patients (41.7%) were in the
D-557/8 Group, and 35 patients (58.3%) were in in the No-D-557/8 Group. The exact PV
types and codon locations of the exon 11 study population are shown in Figure 2.
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Figure 2. Codon location of the PVs in the population of metastatic KIT exon 11 patients treated with first-line imatinib. The
different colors indicate the PVs positions as related to 557/558 critical codons: PVs involving codons upstream of codon
557; PVs involving codon 557; PVs involving codons 557 and 558; PVs involving codon 558; and PVs involving codons
downstream of codon 558. The length of the line indicates the number of codons involved in each KIT exon 11 mutation.
A total of 41 events (progression or death) were observed (68.3%): 18 events in the
D-557/8 group of 25 patients (72%) and 23 events in the No-D-557/8 group of 35 patients
(65.7%). The overall median PFS was 37 months (95% confidence interval (CI): 26.8–47.1).
The median PFS was 24 months (95% CI: 21.3, 26.7) for the D-557/8 Group and 49 months
(95% CI: 39.4, 58.6) for the No-D-557/8 Group (p < 0.001) (Figure 3A).
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Subsequently, in the next analysis, we have divided the group of other PVs than
557/558 deletions (NoD-557/8) into two further subgroups, to investigate the potential
different impact on PFS: (i) patients with KIT Exon 11 deletion or delins in codons other
than 557/558; (ii) patients with duplication, insertion or SNV of all codons. The median
PFS was 43 months (95% CI: 25.1, 60.9) for the patients with deletion or delins in other
codons than 557/558, and 49 months (95% CI: 27.5, 70.4) for patients with duplication,
insertion or SNV (p = 0.002) (Figure 3B).
After a median follow-up of 107 months, 18 events (deaths) were observed (30%): 10
in 25 of D-557/8 patients (40%) and 8 in 35 (23%) of No-D-557/8 patients. The overall
median OS was 102 months (95% CI: 89.8, 114.5). The median OS was 99 months (95% CI:
65.8, 132.2) for the exon 11 557/558 deletions or delins patients, and not reached (NR) for
the group of patients with other mutations (p = 0.14).
Regarding the associations of KIT Exon 11 mutation type and best overall response
(BOR) in metastatic GIST patients treated with first-line imatinib, patients with deletion
or delins regardless of codon regions had a significantly better CR rate (557/558: 40%;
other codons: 37.5%) compared to the patients with other PVs (Dup, Ins or SNV) (5.3%)
(p = 0.006).
2.2.3. Univariate and Multivariate Analysis
Table 3 summarizes the results of the univariable and multivariable prognostic factor
analysis for PFS and overall survival (OS). Gender, performance status, the diameter of
the primitive tumor, lymphopenia, polymorphonuclear (PMN) leucocytosis and KIT exon
11 PV type were found to be statistically significantly associated with PFS in univariable
analyses. In the final multivariable Cox regression model, the following factors were
significant: the female gender (median PFS: 26 versus 50 months, p < 0.001, HR: 0.23), a
primitive tumor diameter ≤ 5 cm (median PFS: 27 versus 63 months, p = 0.017, HR: 3.39), a
PMN leucocyte > 7.5 × 109 (median PFS: 24 versus 49 months, p = 0.006, HR: 0.27) and the
absence of KIT Exon 11 Del or Delins 557/558 (median PFS: 24 versus 45 months, p < 0.001,
HR: 0.12).
Regarding OS, performance status, lymphopenia and PMN leucocytosis were statis-
tically significantly associated in univariable analyses. In the final multivariable model,
only performance status remained statistically significant (median OS: 113 vs. 48 months,
p = 0.029, HR: 3.97).
Therefore, these results showed that, in the population of metastatic KIT exon 11 mu-
tated patients treated with first-line imatinib, the absence of KIT exon 11 deletions or delins
557/558, the female gender, a primitive tumor diameter ≤ 5 cm and polymorphonuclear
leucocytosis > 7.5 × 109/L were significant independent prognostic factors for longer PFS,
while the performance status was the only significant prognostic factor for OS.
The PFS and OS curves were plotted according to each independent prognostic factor
(Figure 3C–F).
Cancers 2021, 13, 993 10 of 15
Table 3. Univariate and multivariate analysis of prognostic factors of PFS and OS in GIST exon 11 mutated patients treated
with first-line imatinib. Gender, performance status, primitive tumor diameter, number of mitoses, liver and peritoneal
metastatic involvement, lymphopenia, polymorphonuclear leucocytosis and KIT exon 11 codon 557 and/or 558 deletion or
deletion/insertion were evaluated in the Cox regression model.
PFS
Univariate Cox Regression Multivariable Cox Regression
HR (95%CI) p-Value HR (95%CI) p-Value
Gender
(F vs. M) 0.46 (0.24–0.89) 0.022 0.23 (0.09–0.53) <0.001
Performance status (PS)
(1/2 vs. 0) 3.64 (1.47–9.03) 0.005 3.13 (0.89–10.98) 0.073
Primitive tumor diameter
(≤5 cm vs. >5 cm) 2.62 (1.13–6.07) 0.025 3.39 (1.25–9.22) 0.017
Mitosis
(≤5/50 HPF vs. >5/50 HPF) 1.14 (0.59–2.21) NS
Gastric site of origin
(No vs. yes) 1.27 (0.58–2.81) NS
Liver and peritoneal involvement
(No vs. yes) 0.83 (0.32–2.14) NS
Lymphopenia
(≤1 vs. <1 G/L) 2.11 (1.01–4.42) 0.046 1.05 (0.35–3.19) 0.92
Polymorphonuclear leucocyte
(>7.5 × 109 vs. ≤7.5 × 109/L) 0.24 (0.11–0.51) <0.001 0.27 (0.10–0.68) 0.006
Exon 11 Del or Delins 557 and/or 558
(No vs. yes) 0.36 (0.19–0.69) 0.002 0.12 (0.04–0.31) <0.001
OS
Univariate Cox Regression Multivariable Cox Regression
HR (95%CI) p-value HR (95%CI) p-value
Gender
(F vs. M) 1.19 (0.48–2.98) NS
Performance status (PS)
(1/2 vs. 0) 6.35 (2.17–18.58) <0.001 3.97 (1.15–13.68) 0.029
Primitive Tumor diameter
(≤5 cm vs. >5 cm) 2.17 (0.60–7.73) NS
Mitosis
(≤5/50 HPF vs. >5/50 HPF) 1.39 (0.50–3.83) NS
Gastric site of origin
(No vs. yes) 0.40 (0.13–1.21) NS
Liver and peritoneal involvement
(No vs. yes) 2.38 (0.63–9.07) NS
Lymphopenia
(≤1 vs. <1 G/L) 3.54 (1.35–9.27) 0.01 2.16 (0.71–6.55) NS
Polymorphonuclear leucocyte
(>7.5 × 109 vs. ≤7.5 × 109/L) 0.38 (0.15–9.81) 0.04 0.76 (0.25–2.38) NS
Exon 11 Del or Delins 557 and/or 558
(No vs. yes) 0.49 (0.20–1.24) NS
CI: confidence interval; Del: deletions; Delins: deletions/insertions; HR: hazard ratio; OS: overall survival; and PFS: progression free
survival.
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3. Discussion
GIST oncogenic dependence on KIT and PDGFRA receptor is a paradigmatic model of
oncogene addiction [22–24]. Imatinib is clinically efficacious in the treatment of advanced
GIST patients, resulting in a median PFS of 20 months and a median overall survival
(OS) of 57 months [14,25,26]. Although effective in the vast majority of patients, PFS to
imatinib treatment may vary widely [27–29]. We know that in metastatic GIST patients,
the most important predictive factors for response to imatinib are the KIT and PDGFRA
genotypes [16,22]. We have learned that GIST patients harboring mutations in KIT exon
11 are highly sensitive to imatinib and show a deep and prolonged response. GISTs with
KIT exon 9 mutation also benefit from imatinib, but are less sensitive to the standard
dose of 400 mg/die and benefit from the increased dose of imatinib 800 mg/die [13,30].
The exon 11 mutations are the most common KIT mutations, and patients carrying these
PVs represent a heterogeneous subgroup in terms of biological and clinical behavior, with
10% of patients remaining sensitive to imatinib despite the drug-selective pressure and
keepingprogression-free after 10 years of treatment [16,31]. The lack of relevant predictive
or prognostic clinical factors, according to the available data, makes the presence of this
subset of long-term survivors of high biological and clinical interest.
Based on the known predictive role of genotype, the variable clinical outcome in KIT
exon 11 mutated patients could be related to intrinsic molecular features, such as a different
PV type and the gene location of exon 11 KIT mutations. Previous findings on localized
GIST provide the rationale to better investigate this hypothesis [18–20]. Indeed, several
studies showed the prognostic significance of different types of KIT exon 11 mutations for
recurrence-free survival in localized GIST patients treated with surgery [18]. KIT exon 11
deletions and deletions affecting KIT exon 11 codons 557 and/or 558 are associated with
a poor prognosis and have been described as independent adverse prognostic factors for
relapse [18,23]; conversely, other exon 11 KIT mutations, such as insertion and duplication
mutations, are generally associated with a favorable outcome [18].
In terms of metastatic disease, previous studies have addressed the predictive role of
KIT exon 11 PVs on response and survival to imatinib. However, to our knowledge, very
few studies have further subdivided the KIT exon 11 mutated population-based on PVs.
A first study compared the outcomes of patients with the most frequent deletion of
KIT exon 11, the PV delWK557-558 and the deletion of Tyr568-570, which was selected
because these tyrosines represent the first residues to be phosphorylated during activation
and, thus, may be associated with specific effects on KIT signaling pathways. Metastatic
GISTs, carrying one of two types of PVs (n.22 vs. n.14 patients, respectively) and treated
with imatinib, showed no significant difference in terms of response rates, PFS and OS [23].
However, no other PVs were included in the analysis conducted for this study.
A subsequent study investigated the predictive role of KIT exon 11 mutations in a
broader cohort of advanced patients, but with its main focus on PVs’ mutational locations.
The researchers compared the molecular subgroups of advanced GIST treated in the BFR14
study of the French Sarcoma Group divided in terms of PV position: 557/558 codons,
upstream or downstream exon 11 codons. Long-term outcome analysis showed that
patients with alterations involving 557/558 codons developed secondary resistance more
rapidly compared to the patients carrying the most distal exon 11 mutations (codon 559 or
more) [21]. However, the role of a PV’s type, beyond its location, as a predictive biomarker
for imatinib response has not been fully elucidated in metastatic patients.
Our study provides real-world evidence of the impact of type and location of KIT exon
11 PVs on clinical outcomes and response to therapy in advanced GIST patients treated
with first-line imatinib 400. We show in a real-world population that the group of 557/558
mutations is not a homogeneous group in terms of response to imatinib: not all of the
codons 557/558 PVs develop gain secondary resistance to imatinib more rapidly than other
KIT PVs, as a markedly poorer PFS curve is shown for deletions involving codons 557/558.
This result reaches an independent value in the multivariate model. Patients with deletion
or insertion/deletion in codons 557/558 had a median PFS of 24 months; this PFS is in
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line with literature data in the metastatic setting [14], but is shorter compared to patients
with a deletion in other codons (median PFS: 43 months) or patients with duplication,
insertion or SNV (median PFS: 49 months) (p = 0.002). Multivariable prognostic factor
analysis performed to assess the impact of the different baseline covariates on PFS and
OS, showed that the absence of KIT Exon 11 del or delins 557/558, the female gender, a
primitive tumor diameter ≤5 cm and PMN leucocytosis (>7.5 × 109/L) were significant
prognostic factors for longer PFS to first-line imatinib; only performance status remains
statistically significant in the multivariate model for OS.
These data, combined with previous findings in patients with localized diseases,
confirm an aggressive biology of 557/558 exon 11 deletions or delins even in the metastatic
setting, particularly for specific PVs such as the KIT p.W557_K558del, which explains
their high prevalence in advanced GISTs [32]. The shorter PFS associated with 557/558
deletions could be biologically explained by their specifically designated role in the process
of tyrosine kinase activation of the different segments of the KIT receptor. It is known
from previous studies that the oncogenic KIT signaling mechanisms varied depending
on the exact type and location of the PVs [33–35]. The 557/558 codon region contains
residues that exert a critical autoinhibitory role on kinase activity, repressing the ligand-
independent activation. The exon 11 codons 557/558 deletions may perturb KIT kinase
autoinhibition by controlling the a-helical conformation, essentially leading to increased
spontaneous receptor phosphorylation, the activation of Ras/Raf/MAPK, JAK/STAT3
and PI3K/Akt/mTOR downstream signaling pathways, ultimately leading tumor cell
proliferation and the inhibition of apoptosis [36].
To our knowledge and based on the best data available today, this is the study that has
provided the most representative picture of the predictive role of KIT exon 11 pathogenic
variants in metastatic patients treated with first-line imatinib. It remains to be elucidated
whether other convincing factors (such as microenvironment immunological characteristics
or clinical factors not yet investigated) may have a further relevant impact on tumor
response and progression-free survival.
4. Patients and Methods
4.1. Study Population
In the current study, clinicopathological variables and mutational status data were
analyzed from a GIST System database prospectively collected in an Italian referral center
for diagnosis and treatment of soft tissue sarcoma and GIST: the “Sicilian Regional Center
for the Prevention, Diagnosis, and Treatment of Rare and Heredo–Familial Tumors” of the
Section of Medical Oncology of University Hospital Policlinico “P. Giaccone” of Palermo.
In the study the patients afferent to the center between January 2005 and September 2020
were included, based on retrievable tumor specimens in order to centrally repeat muta-
tional analysis. The metastatic GIST patients treated with first-line imatinib 400 therapy
were included in the analyses of the predictive role of mutation type and codon location.
The information collected from these patients included gender, age, site of the origin of
primary tumors, primitive tumor diameter and mitosis, KIT and PDGFRA pathogenic
variant (PV) classification, data on active disease sites, best overall response (BOR) to
imatinib (progression disease (PD), stable disease (SD), partial response (PR), complete
response (CR)) assessed according to response evaluation criteria in solid tumors (RECIST
version 1.1.), progression-free survival (PFS) to imatinib treatment and overall survival
(OS). The association between KIT Exon 11 mutation type and BOR, PFS and OS was evalu-
ated. The clinical, pathological and genetic information were anonymously recorded for all
patients who previously provided written informed consent. This study was conducted in
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
4.2. Mutation Analysis
The diagnosis of GIST was made based on histopathologic assessment and immunohis-
tochemical staining for CD117 antigen expression from local pathology testing of diagnostic
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core biopsies or tumor resections for clinical use. The pathologists, with special interest
in sarcoma pathology, also reported tumor mitoses from 50 HPFs and diameter lesions.
Four (4)-µm thick FFPE tissue sections were deparaffinized with a Deparaffinization So-
lution (Qiagen, Hilden, Germany) and genomic DNA was extracted using a QIAamp
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s in-
structions. Extracted DNA was quantified using a Qubit® 3.0 fluorometer (Thermofisher
Scientific, Waltham, MA, USA) and its quality was assessed by using a SeqStudio Genetic
Analyzer (Applied Biosystem). All GISTs were centrally examined for somatic mutations
in KIT (exons 9, 11, 13 and 17) and PDGFRA (exons 12, 14 and 18) by polymerase chain
reaction (PCR) amplification and direct Sanger sequencing. PCR reactions were run on
Veriti Thermal Cycler (Applide Biosystem) and Sanger sequencing wasperformed using a
BigDye Terminator 3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA, USA) on
the SeqStudio Genetic Analyzer (Applied Biosystem, Foster City, CA, USA), according to
manufacturer’s protocols. PVs were confirmed using Sanger sequencing with a BigDye
Terminator 3.1 Cycle Sequencing Kit (Life Technologies) on the SeqStudio Genetic Analyzer
(Applied Biosystem). Samples that scored negative were further profiled using a targeted
next generation sequencing (NGS) panel for the presence of hot spot mutations in H/K/N
RAS, BRAF and NTRK using an Ion Torrent S5 (Thermofisher Scientific) instrument. For
all detected PVs found, a gene name, a nucleotide change (c.notation) and an amino acid
change (p.notation) were codified. The classification of the variant was performed after
consulting the databases “Catalogue Of Somatic Mutations In Cancer” (COSMIC) and
ClinVar. According to the aim of the study, only the KIT and PDGFRA PVs were included
in the following analyses.
4.3. Statistical Analysis
PFS was calculated from beginning of the imatinib treatment to death by any cause,
disease progression or last follow-up (censored patients). OS was calculated from the
beginning of the imatinib treatment to death by any cause or last follow-up (censored
patients). The analyses of PFS and OS between groups were compared using the Kaplan–
Meier method and a log-rank test. To identify independent prognostic factors for PFS and
OS, univariate and multivariate Cox proportional hazard regression models were built.
All tests were performed with a significance level of p = 0.05. Statistical analyses were
conducted using IBM SPSS Statistics for Windows Version 25.0 (IBM Corporation, Armonk,
NY, USA).
5. Conclusions
From previous studies on GIST, we have learned that, in metastatic patients, the
main predictive factor for the duration of response to imatinib is the genotype [13]. In
the KIT exon 11 mutated patients, who are the most common molecular-based subgroup
of advanced GIST patients, our results reveal the important impact of the PVs’ type and
location on PFS. We detected a significantly shorter PFS for those patients carrying deletions
involving 557/558 codons compared to the patients with deletions in other codons or
patients with duplications, insertions or SNVs. These data, combined with the existing
evidence on the negative role of 557/558 deletion for RFS in localized patients treated with
surgery [18], confirm the aggressive biology of 557/558 exon 11 deletions or delins in the
metastatic setting as well. These findings have potential clinical utility because they only
allow an understanding of why a subgroup of patients responds to imatinib better than
other groups, but also predict at baseline which GIST patients would experience resistance
to treatment earlier. This study also supports the use of stratification by mutational type
and codon location in future clinical trials.
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